LipoScience's EPS (Basic) for the
three
months ended in Sep. 2014 was €-0.22.
Its EPS (Basic) for the trailing twelve months (TTM) ended in Sep. 2014 was €-0.64.
LipoScience's EPS without NRI for the
three
months ended in Sep. 2014 was €-0.22.
Its EPS without NRI for the trailing twelve months (TTM) ended in Sep. 2014 was €-0.63.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using EPS without NRI data.
LipoScience EPS (Diluted) Historical Data
The historical data trend for LipoScience's EPS (Diluted) can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of LipoScience's EPS (Diluted)
For the Diagnostics & Research subindustry, LipoScience's PE Ratio, along with its competitors' market caps and PE Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
LipoScience's PE Ratio Distribution in the Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, LipoScience's PE Ratio distribution charts can be found below:
* The bar in red indicates where LipoScience's PE Ratio falls into.
LipoScience EPS (Diluted) Calculation
EPS (Diluted) is a rough measurement of the amount of a company's profit that can be allocated to one share of its stock. Diluted EPS takes into account all of the outstanding dilutive securities that could potentially be exercised (such as stock options and convertible preferred stock) and shows how such an action would impact earnings per share.
LipoScience's Diluted EPS for the fiscal year that ended in Dec. 2013 is calculated as
EPS (Diluted) for the trailing twelve months (TTM) ended in Sep. 2014 adds up the quarterly data reported by the company within the most recent 12 months, which was €-0.64
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
LipoScience (FRA:LI0) EPS (Diluted) Explanation
EPS is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.
Be Aware
Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.
If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.
LipoScience EPS (Diluted) Related Terms
Thank you for viewing the detailed overview of LipoScience's EPS (Diluted) provided by GuruFocus.com. Please click on the following links to see related term pages.
LipoScience Inc was incorporated under the laws of North Carolina in June 1994 under the name LipoMed, Inc. and reincorporated under the laws of Delaware in June 2000. The Company is a clinical diagnostic company into field of personalized diagnostics based on nuclear magnetic resonance technology. The Company's first diagnostic test, the NMR LipoProfile test, is cleared by the U.S. Food and Drug Administration, and directly measures the number of low density lipoprotein, particles in a blood sample and provides physicians and their patients with actionable information to personalize management of risk for heart disease. The Company's technology platform combines proprietary signal processing algorithms and NMR spectroscopic detection into a clinical analyzer to identify and quantify concentrations of lipoproteins and, potentially, small molecule metabolites. NMR detectors, or spectrometers, analyze a blood plasma or serum sample by subjecting it to a short pulse of radio frequency energy within a strong magnetic field. The Company currently markets NMR LipoProfile test through a direct sales force in 27 states. The Company competes against companies that offer other methods for measuring lipoproteins. Its competitors include Quest Diagnostics, Berkeley HeartLab, Inc., Atherotech, Inc. and SpectraCell Laboratories. The Company is subject to extensive and frequently changing federal, state and local laws and regulations governing various aspects of its business.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
FRA:LI0 has been successfully added to your 